Dr. John Cush RheumNow
3 years 1 month ago
EULAR Points to Consider in Progressing Psoriasis to Psoriatic Arthritis
The transition from psoriasis to PsA – and the early diagnosis of PsA – is of considerable scientific and clinical interest.
https://t.co/OxcpnJ5EOe https://t.co/ggOnwt3wck
Dr. John Cush RheumNow
3 years 1 month ago
Plantar Fasciitis study of 180 PF patients shows no clinically meaningful difference between pts treated with patient advice plus heel cup alone (PA) versus PA and lower limb exercise (PAX) versus PAX plus corticosteroid injection (PAXI) https://t.co/hkDuCOYICy https://t.co/ZGicUqXN8l
Dr. John Cush RheumNow
3 years 1 month ago
Combination Cannabidiol (CBD) & hydroxychloroquine in RA? A phase II trial of IHL-675A (CBD+HCQ) will soon begin; following on phase I and animal studies showing it was tolerated, with no adverse events of concern.IHL-675A was superior to HCQ alone. https://t.co/H90D9LzNSo https://t.co/JiS6HL38Jg
Dr. John Cush RheumNow
3 years 1 month ago
RNase Treatment of Autoimmune Disorders
U1RNP complex, Ro/SSA and La/SSB are major RNA-containing autoantigens associated with autoimmune disorders.
https://t.co/4Q8NGgKvfj https://t.co/QavCtY1E83
Dr. John Cush RheumNow
3 years 1 month ago
Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/vGt12ul6iy https://t.co/044BScmSYc
Dr. John Cush RheumNow
3 years 1 month ago
US claims data shows the incidence rate of Herpes zoster (HZ) to be higher in RA (21.5/1000PY;HR 1.93) than non-RA (7.6/1000PY), increasing with age in RA,≥ 65 yrs -23.4/1000PY), highest w/ steroids and JAK inhibitors https://t.co/yH5bRGEyFh https://t.co/avvHwPkvJB
Dr. John Cush RheumNow
3 years 1 month ago
Bringing pivotal clinical trials to you: announcing RheumNow’s Poster Hall, featuring previously presented, sponsor-generated clinical trial posters designed to educate and inform.
https://t.co/dHg0rrKcQ8 https://t.co/qtUxGg3waX
Dr. John Cush RheumNow
3 years 1 month ago
Infectious Risk with B Cell Therapies in Lupus
A UK registry study of moderate to severe SLE showed that treatment with rituximab or belimumab was not associated with a greater risk of serious infection, when compared to standard of care therapy.
https://t.co/AbqrlU3qpw https://t.co/RlyWaTjWO1
Dr. John Cush RheumNow
3 years 1 month ago
Words of wisdom from Dr. Bharat Kumar, editor of the Rheumatologist @BharatKumarMD https://t.co/VbgI9ew5T8
Dr. John Cush RheumNow
3 years 1 month ago
Cohort comparison of Psoriatic arthritis in 141 males vs 131 females: found psoriasis (BMI , BSA) was worse in males, but PsA worse in females (higher PtGA, PtPnV, TJC, SJC, DAPSA, HAQ-DI, and PsAID-12). Men more likely to get to MDA than females https://t.co/e1mFo0kCtL https://t.co/LfJJZc5Ecp
The CDC estimates that nearly 220,000 children and adolescents had arthritis during 2017–2021. Prevalence (305 per 100,000) increased with age and is higher in 12–17 year olds; non-Hispanic Black or African Americans; those with anxiety or depression; physically inactive; overweight or a heart condition; or lived in a food-insecure or smoking household.
Dr. Jack Cush reviews the news and journal reports and this week, takes on 5 cases/questions from "Ask Cush Anything"
Dr. John Cush RheumNow
3 years 1 month ago
Study of >19K RA pts in National Databank showed that Opioids vs NSAID use had similar MACE risk(20.6 vs 18.9/1000 PY), but opioids had higher mortality (13.5 vs 10.8/1000 PY; HR1.33) & VTE risk(HR=1.41). Opioids are not safer than NSAIDs https://t.co/J56BqYMKM1 https://t.co/xiz4GGUnJC
Dr. John Cush RheumNow
3 years 1 month ago
BE OPTIMAL study: Bimekizumab vs adalumumab in 702 #PsA pts, showed sustained 52 week ACR50 responses at wk 52: 54% BKZ v 50% ADA; PASI 100 61% BKZ v 48% ADA. Serious AE seen in 6.6% of BKZ patients, 1 death and 7.7% w/ Candida (vs 0.7% w/ ADA) https://t.co/4g3j5OoKyy https://t.co/g4SQubSCXg
